A case of permeant neonatal diabetes with KCNJ11 mutation
DOI:
https://doi.org/10.18203/2349-3291.ijcp20232265Keywords:
Neonatal diabetes mellitus, KCNJ11gene, SulphonylureasAbstract
Neonatal diabetes mellitus is considered when there is hyperglycaemia requiring insulin therapy. Phenotypically NDM is classified into three types-transient, permanent and syndromic forms. Permanent NDM-may start in new-born life and is mainly due single gene mutations-KCNJ11 and ABCC8. This mutation is almost 90% manageable with oral sulphonyl ureas. We report a case of Permanent NDM with KCNJ11 mutation who presented in diabetic Ketoacidosis at 4 months of age. Clinical genome sequencing revealed a heterozygous missense variation in exon 1 of the KCNJ11 gene (chr11: g.17387491G>A) that results in the amino acid substitution of cysteine for arginine at codon 201. She was initially treated with insulin for which she had poor glycaemic control. She responded well following the switch over to sulphonylureas with good compliance and has normal development.
References
Beltrand J, Busiah K, Vaivre-Douret L, Fauret AL, Berdugo M, Cavé H, Polak M. Neonatal diabetes mellitus. Frontiers in Pediatrics. 2020:602.
Lemelman MB, Letourneau L, Greeley SA. Neonatal diabetes mellitus: an update on diagnosis and management. Clinics in perinatology. 2018 Mar 1;45(1):41-59.
Letourneau LR, Carmody D, Wroblewski K, Denson AM, Sanyoura M, Naylor RN, Philipson LH, Greeley SA. Diabetes presentation in infancy: high risk of diabetic ketoacidosis. Diabetes Care. 2017 Oct 1;40(10):e147-8.
Carmody D, Pastore AN, Landmeier KA, Letourneau LR, Martin R, Hwang JL, Naylor RN, Hunter SJ, Msall ME, Philipson LH, Scott MN. Patients with KCNJ 11‐related diabetes frequently have neuropsychological impairments compared with sibling controls. Diabetic Medicine. 2016 Oct;33(10):1380-6.
De Franco E, Flanagan SE, Houghton JA, Allen HL, Mackay DJ, Temple IK, Ellard S, Hattersley AT. The effect of early, comprehensive genomic testing on clinical care in neonatal diabetes: an international cohort study. The Lancet. 2015 Sep 5;386(9997):957-63.
Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6. 2 mutations. New England Journal of Medicine. 2006 Aug 3;355(5):467-77.
Madani HA, Fawzy N, Afif A, Abdelghaffar S, Gohar N. Study of Kcnj11 gene mutations in association with monogenic diabetes of infancy and response to sulfonylurea treatment in a cohort study in Egypt. Acta Endocrinologica (Bucharest). 2016 Apr;12(2):157.
Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, Tessmann EH, Juliusson PB, Skrivarhaug T, Pearson ER, Flanagan SE. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. The Lancet diabetes & endocrinology. 2018 Aug 1;6(8):637-46.
